Biological drug and drug delivery-mediated immunotherapy

Xiao, Qingqing; Li, Xiaotong; Li, Yang; Wu, Zhenfeng; Xu, Chen; Chen, Zhongjian; He, Wei

doi:10.1016/j.apsb.2020.12.018

Cited by 116 publications

(71 citation statements)

References 274 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These include liposomes, stable nucleic acid lipid particles (SNALPs), solid lipid nanoparticles (SLNs), pH-responsive lipids, and exosomes ( Table 3 and Fig. 6 ) 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 .…”

Section: Sirna Delivery Systems For Treatment Of Ali/ardsmentioning

confidence: 99%

“…Despite the several advantages of cationic liposomes, including efficient in vitro transfection, high loading capacity, structural flexibility, excellent biocompatibility, biodegradability, and ease of large-scale production, their advancement is still hindered by some drawbacks. These include safety concerns, nonspecific tissue uptake, and premature siRNA release due to their interaction with proteins, lipoproteins, and the extracellular matrix 117 , 118 , 119 , 120 . Furthermore, cationic liposomes are highly toxic to immune cells and can induce their clearance by macrophages through activation of the complement cascade 116 , 119 .…”

Section: Sirna Delivery Systems For Treatment Of Ali/ardsmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome

Zoulikha

Xiao

Boafo

et al. 2022

Acta Pharmaceutica Sinica B

Self Cite

142

View full text Add to dashboard Cite

The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of several unmet medical needs, including acute lung injury/acute respiratory distress syndrome (ALI/ARDS) wherein siRNA may be implemented to modify the expression of pro-inflammatory cytokines and chemokines at the mRNA level. The clear anatomy, accessibility, and relatively low enzyme activity make the lung a good target for local siRNA therapy. However, the clinical translation of siRNA is hampered by the inefficient delivery of siRNA therapeutics to the target cells due to the properties of naked siRNA. Thus, this review will focus on the various delivery systems that can be used and the different barriers that need to be surmounted for the development of stable inhalable siRNA formulations for human use before siRNA therapeutics for ALI/ARDS become available in the clinic.

show abstract

Section: Sirna Delivery Systems For Treatment Of Ali/ardsmentioning

confidence: 99%

Section: Sirna Delivery Systems For Treatment Of Ali/ardsmentioning

confidence: 99%

Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome

Zoulikha

Xiao

Boafo

et al. 2022

Acta Pharmaceutica Sinica B

Self Cite

142

View full text Add to dashboard Cite

show abstract

“…Chemoimmunotherapy refers the combination of chemotherapy and immunotherapy 1 , 2 . Chemotherapy uses drugs to kill or slow the growth of cancer cells while immunotherapy stimulates or restores the ability of the immune system to fight against cancer.…”

Section: Introductionmentioning

confidence: 99%

Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response

Hou

Huang

Pang

et al. 2021

Acta Pharmaceutica Sinica B

Self Cite

View full text Add to dashboard Cite

Co-delivery of chemotherapeutics and immunostimulant or chemoimmunotherapy is an emerging strategy in cancer therapy. The precise control of the targeting and release of agents is critical in this methodology. This article proposes the asynchronous release of the chemotherapeutic agents and immunostimulants to realize the synergistic effect between chemotherapy and immunotherapy. To obtain a proof-of-concept, a co-delivery system was prepared via a drug-delivering-drug (DDD) strategy for cytosolic co-delivery of Poly I:C, a synthetic dsRNA analog to activate RIG-I signaling, and PTX, a commonly used chemotherapeutics, in which pure PTX nanorods were sequentially coated with Poly I:C and mannuronic acid via stimulating the RIG-I signaling axis. The co-delivery system with a diameter of 200 nm enables profound immunogenicity of cancer cells, exhibiting increased secretion of cytokines and chemokines, pronounced immune response in vivo , and significant inhibition of tumor growth. Also, we found that intracellularly sustained release of cytotoxic agents could elicit the immunogenicity of cancer cells. Overall, the intracellular asynchronous release of chemotherapeutics and immunomodulators is a promising strategy to promote the immunogenicity of cancer cells and augment the antitumor immune response.

show abstract

“…Low LPC doses can promote selective ICAM-1 and VCAM-1 upregulation in human and rabbit ECs in vitro, suggesting it has the potential to influence leukocyte recruitment [26,27]. Indeed, in vivo analyses of the mesenteric microvasculature in rats have shown that LPC can promote leukocyte rolling and adherence through the upregulation of ICAM-1 and P-selectin via a mechanism potentially associated with nitric oxide (NO) production given that inhibiting endothelial NO release can induce P-selectin expression [28][29][30].…”

Section: Introductionmentioning

confidence: 99%

Lysophosphatidylcholine promotes intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression in human umbilical vein endothelial cells via an orphan G protein receptor 2-mediated signaling pathway

Zhang

Liu

et al. 2021

Bioengineered

View full text Add to dashboard Cite

show abstract

Biological drug and drug delivery-mediated immunotherapy

Cited by 116 publications

References 274 publications

Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome

Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome

Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response

Lysophosphatidylcholine promotes intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression in human umbilical vein endothelial cells via an orphan G protein receptor 2-mediated signaling pathway

Contact Info

Product

Resources

About